Crispr’s Next Frontier: Treating Common Conditions
By Amy Dockser Marcus,
The Wall Street Journal
| 05. 07. 2021
At the age of 38, Katherine Wilemon suffered a heart attack as she carried a ceramic pot into her backyard garden in Los Angeles. Now 53, the mother of two eats right, exercises and takes cholesterol-lowering medication—but it may still not be enough.
“I live with the anxiety of having another heart attack,” says Ms. Wilemon, whose genetic disorder causes high cholesterol levels and a risk for heart attack or stroke that is up to 20 times that of people without it.
In the next decade, Crispr-Cas9 and other new gene-editing techniques may protect the health not only of Ms. Wilemon and others with familial hypercholesterolemia but millions of people with a range of conditions, including chronic pain and diabetes. Rather than take drugs for years or even decades, for example, at-risk people might be able to protect themselves with a one-and-done Crispr therapy.
It has been a year of profound change that is still transforming all aspects of society. Science has brought revolutionary technologies from the lab into people’s daily lives. Covid-19 vaccines and Crispr gene editors both built...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...